Clinical Trials
29 trialsNCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03786081 2026-04-14
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen Inc.
Phase 1/2 Terminated
NCT05589597 2025-08-22
AUDREY
Enterome
Phase 1/2 Terminated
NCT02521051 2025-05-13
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT03024437 2025-03-20
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
Phase 1/2 Terminated
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03376659 2024-02-05
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Phase 1/2 Terminated
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT03555149 2023-11-07
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Hoffmann-La Roche
Phase 1/2 Terminated
NCT01884740 2022-08-09
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00996502 2019-03-27
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Columbia University
Phase 1/2 Terminated
NCT01090830 2018-02-23
HCH003
Holy Cross Hospital, Florida
Phase 1/2 Terminated
NCT00934440 2017-06-14
5-AZ
University of Kansas Medical Center
Phase 1/2 Terminated
NCT00728845 2017-05-23
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Terminated
NCT00351039 2017-03-23
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00604461 2017-03-23
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT01937715 2016-08-18
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Pfizer
Phase 1/2 Terminated
NCT01189240 2015-12-14
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00684996 2014-05-15
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00819754 2014-01-14
IXO+A
Ottawa Hospital Research Institute
Phase 1/2 Terminated
NCT00410774 2012-09-17
Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
University of California, San Francisco
Phase 1/2 Terminated
NCT00307723 2009-08-10
Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer
Massachusetts General Hospital
Phase 1/2 Terminated